Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28763685 | 0.88 | SMN1; SMN2 (0.44) | MEN1GAAKMT2AAAK1TDP1 | |
| SCHEMBL5094334 | 0.86 | MEN1 (0.54) | MEN1GAAKMT2AAAK1TDP1 | |
| SCHEMBL5094330 | 0.86 | MEN1 (0.54) | MEN1GAAKMT2AAAK1TDP1 | |
| SCHEMBL659421 | 0.85 | MEN1 (0.50) | MEN1GAAKMT2AAAK1TDP1 | |
| SCHEMBL23089857 | 0.81 | CA1 (0.49) | MEN1GAAKMT2AAAK1TDP1 | |
| SCHEMBL6131636 | 0.81 | MEN1 (0.42) | MEN1GAAKMT2AAAK1TDP1 | |
| SCHEMBL23089858 | 0.81 | CA1 (0.49) | MEN1GAAKMT2AAAK1TDP1 | |
| SCHEMBL590719 | 0.80 | MEN1 (0.41) | MEN1GAAKMT2AAAK1TDP1 | |
| SCHEMBL29728278 | 0.80 | MEN1 (0.45) | MEN1GAAKMT2AAAK1TDP1 | |
| SCHEMBL25955311 | 0.80 | MEN1 (0.41) | MEN1GAAKMT2AAAK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| EP-0481522-B1 | Novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | MERRELL PHARMA INC (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5527795-A | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | MERRELL PHARMACEUTICALS INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5491143-A | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-02-13 | — | — | US | disclosed |
| US-5430145-A | Analgesics, reduction of drug withdrawal symptoms, hypotensive agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0481522-A1 | Novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | MERRELL PHARMACEUTICALS INC. (US) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP3, DPP7, DPP9 | MEN1 3217/4885GAA 373/4885KMT2A 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.